Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery
Company Calls Off Inhaled Remdesivir Program
HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.
